JI LIN AO DONG: The solution for nebulized inhalation of terbutaline sulfate has completed drug registration
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, JI LIN AO DONG announced that its holding subsidiary, Yanji Pharmaceutical Group Co., Ltd. (referred to as "Yanji Pharmaceutical"), has received the "Drug Registration Certificate" for "Sulfate Terbutaline Nebulization Solution" issued by the National Medical Products Administration. The indications for sulfate terbutaline nebulization solution are: relief of bronchial asthma, chronic bronchitis, emphysema, and bronchospasm associated with other pulmonary diseases
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments